ArticleBritish journal of pharmacology2018
Inhibition of human N- and T-type calcium channels by an ortho-phenoxyanilide derivative, MONIRO-1.
Article in British journal of pharmacology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 14 citations in OpenAlex.
- Article
- Inhibition of N-type calcium channels by phenoxyaniline and sulfonamide analogues.RSC medicinal chemistry · 2024Article
- µ-Theraphotoxin Pn3a inhibition of CaeLife · 2022Article
- Inhibition of N-type calcium ion channels by tricyclic antidepressants - experimental and theoretical justification for their use for neuropathic pain.RSC medicinal chemistry · 2022Article
- Analgesic transient receptor potential vanilloid-1-active compounds inhibit native and recombinant T-type calcium channels.British journal of pharmacology · 2019Article
- Inhibition of human N- and T-type calcium channels by an ortho-phenoxyanilide derivative, MONIRO-1.British journal of pharmacology · 2018Article
- Recent advances in targeting ion channels to treat chronic pain.British journal of pharmacology · 2018Article
- Betulinic acid analogs inhibit N- and T-type voltage-gated calcium channels to attenuate nerve-injury associated neuropathic and formalin models of pain.Neurobiology of pain (Cambridge, Mass.)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
background and purposeVoltage-gated calcium channels are involved in nociception in the CNS and in the periphery. N-type (Ca EXPERIMENTAL APPROACH: In this study, whole-cell patch clamp electrophysiology was used to assess the potency and mechanism of action of a novel ortho-phenoxylanilide derivative, MONIRO-1, against a panel of voltage-gated calcium channels including Ca KEY
resultsMONIRO-1 was 5- to 20-fold more potent at inhibiting human T-type calcium channels, hCa CONCLUSIONS AND IMPLICATIONS: Selectivity, potency, reversibility and multi-modal effects distinguish MONIRO-1 from other low MW inhibitors acting on Ca LINKED ARTICLES: This article is part of a themed section on Recent Advances in Targeting Ion Channels to Treat Chronic Pain. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v175.12/issuetoc.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.